Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cidara Thera (CDTX)

Cidara Thera (CDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cidara Thera 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 USA

www.cidara.com Employees: 69 P: 858-752-6170

Description:

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.

Key Statistics

Overview:

Market Capitalization, $K 106,544
Enterprise Value, $K 70,764
Shares Outstanding, K 7,047
Annual Sales, $ 63,910 K
Annual Net Income, $ -22,930 K
Last Quarter Sales, $ 300 K
Last Quarter Net Income, $ -91,210 K
EBIT, $ -121,290 K
EBITDA, $ -121,090 K
60-Month Beta 0.99
% of Insider Shareholders 7.64%
% of Institutional Shareholders 35.82%
Float, K 6,508
% Float 92.36%
Short Volume Ratio 0.68

Growth:

1-Year Return 19.11%
3-Year Return -48.57%
5-Year Return -67.83%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 88.79%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.38 on 11/07/24
Next Earnings Date N/A
Earnings Per Share ttm -6.93
EPS Growth vs. Prev Qtr -16.10%
EPS Growth vs. Prev Year -32.22%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 04/24/24

CDTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -69.64%
Return-on-Assets % -33.73%
Profit Margin % -35.88%
Debt/Equity 0.00
Price/Sales 1.72
Price/Cash Flow N/A
Price/Book 0.95
Book Value/Share 18.60
Interest Coverage -0.23
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar